Advanced Human Immunodeficiency Virus Disease in Botswana Following Successful Antiretroviral Therapy Rollout: Incidence of and Temporal Trends in Cryptococcal Meningitis
Author(s) -
Mark W. Tenforde,
Margaret Mokomane,
Tshepo Leeme,
Raju K K Patel,
Nametso Lekwape,
Chandapiwa Ramodimoosi,
Bonno Dube,
Elizabeth A. Williams,
Kelebeletse O. Mokobela,
Ephraim Tawanana,
Tlhagiso Pilatwe,
William James Hurt,
Hannah K Mitchell,
Doreen L Banda,
Hunter H. Stone,
Mooketsi Molefi,
Kabelo Mokgacha,
Heston Phillips,
Paul C. Mullan,
Andrew P. Steenhoff,
Yohana Mashalla,
Madisa Mine,
Joseph N Jarvis
Publication year - 2017
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/cix430
Subject(s) - medicine , incidence (geometry) , population , referral , meningitis , pediatrics , antiretroviral therapy , confidence interval , cryptococcosis , disease burden , demography , human immunodeficiency virus (hiv) , immunology , environmental health , viral load , family medicine , physics , sociology , optics
Botswana has a well-developed antiretroviral therapy (ART) program that serves as a regional model. With wide ART availability, the burden of advanced human immunodeficiency virus (HIV) and associated opportunistic infections would be expected to decline. We performed a nationwide surveillance study to determine the national incidence of cryptococcal meningitis (CM), and describe characteristics of cases during 2000-2014 and temporal trends at 2 national referral hospitals.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom